Atrial Fibrillation Research Spurs Updates to Treatment Guidelines
January 1, 2011|Family Medicine
Author and Disclosure Information
As for additional research, “We need to know how to prevent [atrial fibrillation] in the first place, and we need to understand thoroughly the long-term outcomes of ablation therapy,” Dr. Curtis said.
Dr. Wann had no financial conflicts to disclose. Several of the writing group members, including Dr. Curtis, disclosed serving as a speaker or consultant, or receiving research funding from multiple pharmaceutical companies including Medtronic, Boston Scientific, AstraZeneca, Sanofi-Aventis, and GlaxoSmithKline.
